Abstract

Ahmed Mohamed Othman, Mahmoud Mahyoob Alburyhi*, Ghada Hassan Al-Hadad

ABSTRACT

Captopril is a sulfhydryl-containing angiotensin-converting enzyme inhibitor which is the enzyme that converts angiotensin-I to angiotensin II and may also reduce the degradation of bradykinin. It is used in the management of hypertension, heart failure, myocardial infarction and in diabetic nephropathy. Therefore, it can be used as a model of mouth dissolving tablets MDTs as a more bioavailable form than conventional tablets. The main objective of the present study was to stability studies were performed to know the development of formulation and evaluation of Captopril mouth dissolving tablets MDTs to improve the bioavailability of Captopril. The selected stored Captopril MDTs F1 were evaluated for weight variation, uniformity of thickness, content uniformity, friability, hardness, disintegration time and wetting time at time intervals (1,2,3,4,5 & 6 months). Dissolution rate of F1 selected stored Captopril MDTs seemed to be slightly affected by storage conditions but still within acceptable range. Drug content of F1 selected stored Captopril MDTs was found to be 98.3% at the end of the six-months storage period which was complied with the pharmacopeial requirements. The percent of drug remaining of F1 selected stored Captopril MDTs was found to be 90.4% at the end of the 6 months. storage period which was complied with the pharmacopeial requirements. It was concluded that the F1 of Captopril MDTs was found to be stable at 40oC/75%RH for 6 months.